AIM ImmunoTech (NYSE American: AIM) announced that data from a completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer study using Ampligen (rintatolimod) was accepted as a late‑breaking abstract for presentation at the 40th Annual SITC Meeting (November 5-9, 2025) in National Harbor, MD.
Poster details: Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes; Presenting author: Mackenzy M. Radolec, MD; Abstract #1343; Date: Friday, November 7, 2025; Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
AIM ImmunoTech (NYSE American: AIM) ha annunciato che i dati di uno studio di Fase 2 su cancro ovarico avanzato ricorrente resistente al cisplatino che utilizza Ampligen (rintatolimod) sono stati accettati come abstract di ultima ora per una presentazione al 40° Annual SITC Meeting (5-9 novembre 2025) a National Harbor, MD.
Dettagli del poster: Titolo: Uno Studio di Fase II di Chemiantimunoterapia Locoregionale in Ovariana Recidiva Sensibile al Platino Scatena una Risposta Linfotattica T che Correlata con gli Esiti Clinici; Autore presentatore: Mackenzy M. Radolec, MD; Abstract #1343; Data: Venerdì 7 novembre 2025; Luogo: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
AIM ImmunoTech (NYSE American: AIM) anunció que datos de un estudio de Fase 2 en cáncer de ovario avanzado recurrente resistente al cisplatino que utiliza Ampligen (rintatolimod) fueron aceptados como un resumen de última hora para su presentación en la 40ª Reunión Anual SITC (5-9 de noviembre de 2025) en National Harbor, MD.
Detalles del póster: Título: Un ensayo de Fase II de quimioinmunoterapia locorregional combinada en cáncer de ovario recidivado sensible al platino que desencadena una respuesta linfocitotáctica T que se correlaciona con los resultados clínicos; autor presentador: Mackenzy M. Radolec, MD; Abstract #1343; Fecha: viernes, 7 de noviembre de 2025; Ubicación: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
AIM ImmunoTech (NYSE American: AIM)은 Ampligen(rintatolimod)을 사용한 플라티넘에 내성이 있는 재발성 진행성 난소암에 대한 2상 연구의 데이터가 40th Annual SITC Meeting에서 최종 발표 초록으로 채택되었음을 발표했습니다 (2025년 11월 5-9일, National Harbor, MD).
포스터 세부사항: 제목: 재발성 플래티넘 민감한 난소암에서의 경부 지역 혈청-면역 치료의 2상 시험이 임상 결과와 상관관계가 있는 T 림포토틱 반응을 유발합니다; 발표 저자: Mackenzy M. Radolec, MD; 초록 번호 1343; 날짜: 2025년 11월 7일 금요일; 장소: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
AIM ImmunoTech (NYSE American: AIM) a annoncé que les données développées dans une étude de Phase 2 sur un cancer de l’ovaire avancé récurant résistant au cisplatine utilisant Ampligen (rintatolimod) ont été acceptées comme un abstract de dernière minute pour la présentation lors de la 40e réunion annuelle SITC (5-9 novembre 2025) à National Harbor, MD.
Détails du poster : Titre : Un essai de phase II de chimiimmunothérapie locorégionale combinée dans le cancer ovarien récidivant sensible au platine qui déclenche une réponse lymphotactique T corrélée aux résultats cliniques ; Auteur présentateur : Mackenzy M. Radolec, MD; Abstract #1343; Date : vendredi 7 novembre 2025; Lieu : Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
AIM ImmunoTech (NYSE American: AIM) gab bekannt, dass Daten aus einer Phase-2-Studie zu rezidivierendem fortgeschrittenem platinresistentem Ovarialkarzinom, die Ampligen (rintatolimod) verwendet, als kurzfristig verabschiedetes Abstract für eine Präsentation auf dem 40. SITC-Jahrestagung (5.–9. November 2025) in National Harbor, MD, angenommen wurden.
Poster-Details: Titel: Eine Phase-II-Studie zu einer Kombination aus lokoregionaler Chemoimmuntherapie bei rezidiviertem platinempfindlichem Ovarialkarzinom, die eine T-Lymphotaktische Reaktion auslöst, die mit klinischen Ergebnissen korreliert; der präsentierende Autor: Mackenzy M. Radolec, MD; Abstract Nr. 1343; Datum: Freitag, 7. November 2025; Ort: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
AIM ImmunoTech (NYSE American: AIM) أعلنت أن بيانات من دراسة المرحلة الثانية لسرطان المبيض المتكرر المتقدم المقاوم للسيبلاستي باستخدام Ampligen (rintatolimod) قد تم قبولها كملخص متأخر للعرض في الاجتماع السنوي الأربعين SITC (5-9 نوفمبر 2025) في National Harbor، MD.
تفاصيل الملصق: العنوان: تجربة المرحلة الثانية من العلاج الكيميائي المناعي الموضعي-الجهازي المدمج في سرطان المبيض الحسّاس للبلاتين والمتكرر يثير استجابة لمفاوية T ترتبط بالنتائج السريرية؛ المؤلف المقدم: Mackenzy M. Radolec, MD; الملخص رقم 1343; التاريخ: الجمعة 7 نوفمبر 2025; المكان: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
11/04/2025 – 09:05 AM
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the 40th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD.
Details of the poster presentation are as follows:
Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes
Presenting Author: Mackenzy M. Radolec, MD, Clinical Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Women’s Hospital
Abstract Number: 1343
Date: Friday, November 7, 2025
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
For more information about the SITC Annual Meeting, please visit sitcancer.org.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com
FAQ
What did AIM (AIM) announce about the SITC 2025 meeting on November 4, 2025?
AIM said a late‑breaking abstract of Phase 2 data using Ampligen in cisplatin‑resistant advanced recurrent ovarian cancer was accepted for presentation at SITC 2025.
When and where will AIM’s abstract (Abstract #1343) be presented at the SITC meeting?
Abstract #1343 will be presented on Friday, November 7, 2025 at Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center, National Harbor, MD.
Who is the presenting author for AIM’s Ampligen ovarian cancer poster at SITC 2025?
The presenting author is Mackenzy M. Radolec, MD, Clinical Assistant Professor, UPMC Magee‑Women’s Hospital.
What is the clinical focus of the AIM ImmunoTech abstract at SITC (AIM)?
The abstract reports Phase 2 trial data on combination locoregional chemoimmunotherapy with Ampligen in recurrent platinum‑sensitive/ cisplatin‑resistant ovarian cancer and a T lymphotactic response correlated with outcomes.
How can investors find more information about the SITC Annual Meeting where AIM will present?
Investors can visit sitcancer.org for meeting schedules, session details, and presenter information.